In Brief: Abiomed
This article was originally published in The Gray Sheet
Executive SummaryAbiomed: Receives premarket approval application supplement to broaden the indications for its BVS-5000 biventricular support system to include "all patients with recoverable heart function," the firm states. In 1993 the device was approved for "temporary circulatory support of patients who fail to wean from cardiopulmonary bypass following heart surgery," the firm says. The recently approved indications cover "patients suffering from acute cardiac disorders such as, but not limited to, viral myocarditis"...
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.